Antifungal drug discovery, six new molecules patented after 10 years of feast: Why do we need new patented drugs apart from new strategies?

Recent Patents on Anti-Infective Drug Discovery

Volumn 2, Issue 3, 2007, Pages 182-187

  Krcmery, Vladimir ^a,b   Kalavsky, Erich ^a,b  

^a St Elizabeth University College of Health and Social Sciences   (Slovakia)

^b ST ELIZABETH CANCER INSTITUTE   (Slovakia)

Author keywords

Anidulafungin; Caspofungin; Micafungin; Mycograb; Posaconazole; Ravuconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIMETABOLITE; CASPOFUNGIN; COTRIMOXAZOLE; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MYCOGRAB; NYSTATIN; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG USE; FEBRILE NEUTROPENIA; HUMAN; MONOTHERAPY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; DRUG COSTS; FUNGI; HUMANS; MYCOSES; PATENTS AS TOPIC;

EID: 36749066898     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489107782497317     Document Type: Review

References (39)

1. Seok, P.J., Yu, K.A., Kim, S.Y., Song, Y.J., Kang-Pil, K., Yoon, Y.S., Han, M.R.: WO07052943 (2007).
2. Pachl J, Svoboda P, Jacobs F, et al. For the mycograb invasive candidiasis study group. A randomized, blinded, multicenter trial of lipid-associated amphotericin b alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42: 1404-1413.
3. Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 2005; 27(3): 135-40.
4. EORTC. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC international antimicrobial therapy cooperative group. Am J Med 1989; 86(6 Pt 1): 668-72.
5. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole, prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995; 171(6): 1545-52.
6. Herbrecht R, Denning DW, Patterson TF, et al. Invasive Fungal infections group of the cuTopean organisation for research and treatment of cancer and the global aspergillus study group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408-15.
7. Kremery V Jr, Kovacicova G. Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Slovak Fungaemia study group. Diagn Microbiol Infect Dis 2000; 36(1): 7-11.
8. Walsh TJ, Finbcrg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340(10): 764-71.
9. Ostrosky-Zeichner L, Oude Lashof AM, Kullbcrg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22(11): 651-55.
10. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42(2): 244-51.
11. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by flucanazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366(9495): 1435-42.
12. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N EngI J Med 1991; 325(18):1274-77.
13. Bennett JE, lzumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 2004; 48(5): 1773-77.
14. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44(3): 747-51.
15. Kremery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50(4): 243-60.
16. Kremery V, Spanik S. Trichosporon fungaemia after prophylactic itraconazol. Acta Chemother 2002; 5, 113-115.
17. Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005; 40(4): 35-37.
18. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39(4): 584-87.
19. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39(5): 743-46.
20. Pannaraj PS, Walsh TJ, Baker CJ. Advances in antifungal therapy. Pediatr Infect Dis J 2005; 24(10): 921-22.
21. Pfaller MA, Messer SA, Hollis RJ, Jones RN. SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46(4): 1032-37.
22. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36(9): 1122-31.
23. Maertens J, Raad I, Petrikkos G, et al. Caspofungin salvage Aspergillosis Study Group Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39(11): 1563-71.
24. Wolfgang, J., Thomas, V.H., Edgar, V.: W007039226 (2007).
25. Howard, J.L., Eric, M.C., Anthony, P.D., Duncan, S.M., Anthony, S.P.: EP1762567 (2007).
26. Saul, Y.: W007029258 (2007).
27. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42(10): 1398-403.
28. Michaelides, M.R., McClellan, W.J., Frey, R.R., Curtin, M.L., Steinman, D.H., Dai, Y., Holms, J.H.: W007067781 (2007).
29. Loeffler J, Stevens DA. Antifungal drug resistance. Clin Infect Dis 2003; 36(Suppl 1): S31-41.
30. Dismukes WE. Antifungal therapy: lessons learned over the past 27 years. Clin Infect Dis 2006; 42(9): 1289-96.
31. Elizabeth S, Dodds A, Russell L, James SL, Craig M, David A. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43: S28-S39.
32. Elias KS, George A, Eleftherios M. New agents for the treatment of fungal infections: Clinical efficacy and gaps in coverage. Chn Infect Dis 2006; 43: p. 1060-1068.
33. Jose AV, Jack DS. Anidulafungin: A Novel Echinocandin. Clin Infect Dis 2006; 43: 215-22.
34. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42: 1726-1734.
35. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42: 1179-1186.
36. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-responsc study of micaungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-849.
37. Hiemenz J, Cagnioni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micaftingin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chernother 2005; 49(4): 1331-36.
38. Mora-Duarte J, Betts R, Rotstein C, et al. caspofungin invasive candidiasis study group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347(25): 2020-29.
39. Jarvis B, Figgitt DP, Scott LJ. Drugs. Micafungin 2004; 64(9): 969-982.